Compare ONL & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ONL | FATE |
|---|---|---|
| Founded | 2021 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 111.5M | 121.1M |
| IPO Year | N/A | 2013 |
| Metric | ONL | FATE |
|---|---|---|
| Price | $2.26 | $1.01 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 7 |
| Target Price | N/A | ★ $3.92 |
| AVG Volume (30 Days) | 308.1K | ★ 1.4M |
| Earning Date | 11-06-2025 | 11-13-2025 |
| Dividend Yield | ★ 3.59% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $149,775,000.00 | $7,137,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.46 | $0.66 |
| 52 Week High | $4.25 | $1.99 |
| Indicator | ONL | FATE |
|---|---|---|
| Relative Strength Index (RSI) | 55.79 | 42.09 |
| Support Level | $1.97 | $0.95 |
| Resistance Level | $2.28 | $1.12 |
| Average True Range (ATR) | 0.10 | 0.07 |
| MACD | 0.04 | -0.00 |
| Stochastic Oscillator | 93.06 | 24.69 |
Orion Properties Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased on a single-tenant net lease basis to creditworthy clients. The portfolio of the company includes traditional office buildings, governmental offices, medical offices, laboratories, and others. The Company operates in one business segment: direct ownership and operation of commercial real estate.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.